US company Novavax says its Covid-19 vaccine demonstrated a final efficacy of 90.4% against mild, moderate, and severe disease caused by original strain in a phase 3 trial in UK.
The vaccine maker also said ts shot was highly effective and also protected against variants in a large during late-stage study in the US and Mexico.
The vaccine was about 90 per cent effective overall and preliminary data showed it was safe, the company said.
While demand for Covid-19 shots in the US has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.